Aim of this non-interventional study is to investigate the tolerability of Effentora® in cancer pain patients with breakthrough pain under real-life conditions in clinical practice.
In addition to the effectiveness of Effentora® therapy, safety, general feasibility and the impact of therapy on the patients' quality of life are of interest.
Study Type
OBSERVATIONAL
Enrollment
600
prescribed as per local Summary of Product Characteristics (SmPC) for 4 weeks duration
Cephalon GmbH
Munich, Bavaria, Germany
pain relief
to show adequate pain relief within 10 minutes
Time frame: 4 weeks
occurrence of adverse events
document the tolerability of Effentora®
Time frame: 4 weeks
Change in level of breakthrough pain
pursue the possible changes in the history of breakthrough pain during treatment with Effentora
Time frame: 4 weeks
presence of specific triggers for breakthrough pain
to investigate the presence of specific triggers (directly or indirectly) with breakthrough pain
Time frame: 4 weeks
quality of life
to document the impact of breakthrough pain in different areas of patients' lives and their changes during treatment with Effentora®
Time frame: 4 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.